Meeting
2012 Gastrointestinal Cancers Symposium
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.
Authors
Fatima A. Rangwala
Duke University Medical Center, Durham, NC
Fatima A. Rangwala , Johanna C. Bendell , Mark Kozloff , Christy Arrowood , Jennifer Meadows , Sandra Ellen Tourt-Uhlig , Jennifer Murphy , Kellen Meadows , Michael Morse , Hope Elizabeth Uronis , Shiaowen David Hsu , Yousuf Zafar , Herbert Hurwitz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon and Rectum
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Clinical Trial Registration Number
NCT00849550
Citation
J Clin Oncol 30, 2012 (suppl 4; abstr 490)
DOI
10.1200/jco.2012.30.4_suppl.490
Abstract #
490
Poster Bd #
C13
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A multicenter, phase 1 study of AB011, a recombinant humanized anti-CLDN18.2 monoclonal antibody, as monotherapy and combined with capecitabine and oxaliplatin (CAPOX) in patients with advanced solid tumors.
First Author: Jin Li
Poster
2013 Gastrointestinal Cancers Symposium
A phase I dose-finding study of everolimus in combination with capecitabine and oxaliplatin (XELOX) as the first-line chemotherapy for patients with advanced gastric cancer.
First Author: Inkeun Park
Poster
2011 ASCO Annual Meeting
Phase I study of dasatinib in combination with capecitabine, oxaliplatin, and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.
First Author: J. H. Strickler
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase 1/2 evaluation of revumenib in patients with advanced colorectal cancer and other solid tumors.
First Author: Aparna Raj Parikh